California-based AI biotechnology company Verge Genomics has entered a multi-target partnership with Alexion, a subsidiary of AstraZeneca, to identify novel drug targets for rare neurodegenerative and neuromuscular diseases.
The four-year agreement will see Verge receive up to USD 42 million that comprises an upfront fee, equity, and near-term payments, with a potential deal value of USD 840 million plus potential royalties.
The collaboration will leverage Verge's CONVERGE platform, which combines human tissue datasets with AI, to identify and validate therapeutic targets for rare diseases. Alexion will have the option to license and advance successful targets through clinical development and commercialization. Through this partnership, AstraZeneca will also take an equity position in Verge Genomics.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.